SEC 13F Intelligence

Managers / Q4 2023 · view latest →

DAFNA Capital Management LLC

CIK 0001389933 · 10990 WILSHIRE BOULEVARD, SUITE 1400, LOS ANGELES, CA, 90024 · (310) 954-3200

Reported Value
$417M
Q4 2023
Positions
76
Filings on Record
30
2019–present window
Filed
Feb 14, 2024
original filing

Summary

Dafna Capital Management LLC reported $417M in U.S.-listed holdings across 76 positions for Q4 2023.

Its largest position, Spdr S P Biotech Etf, represents 10.4% of the portfolio.

Compared with Q3 2023, the fund opened 7 new positions and exited 6.

Portfolio Metrics

Turnover
+4.4%
vs prior filed quarter
Top-10 Concentration
+49.6%
share of reported value
Largest Position
+10.4%
Spdr S P Biotech Etf
New / Exited
7 / 6
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $201MQ4 ’18Q1 ’19: $232MQ2 ’19: $266MQ3 ’19: $266MQ4 ’19: $291MQ4 ’19Q1 ’20: $240MQ2 ’20: $347MQ3 ’20: $308MQ4 ’20: $336MQ4 ’20Q1 ’21: $421MQ2 ’21: $478MQ3 ’21: $377MQ4 ’21: $398MQ4 ’21Q1 ’22: $384MQ2 ’22: $367MQ3 ’22: $372MQ4 ’22: $355MQ4 ’22Q1 ’23: $334MQ2 ’23: $366MQ3 ’23: $321MQ4 ’23: $417MQ4 ’23Q1 ’24: $439MQ2 ’24: $419MQ3 ’24: $423MQ4 ’24: $393MQ4 ’24Q1 ’25: $353MQ2 ’25: $362MQ3 ’25: $405MQ4 ’25: $431MQ4 ’25Q1 ’26: $440Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 66.6%Other: 14.9%ETP: 13.7%ADR: 3.8%US DOMESTIC: 1.0%
  • Common Stock · 66.6% · $278M
  • Other · 14.9% · $62M
  • ETP · 13.7% · $57M
  • ADR · 3.8% · $16M
  • US DOMESTIC · 1.0% · $4M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2023 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
SG7SAGE THERAPEUTICS INCNEW+245.0K245.0K+$5M$5M
SPRYARS PHARMACEUTICALS INCNEW+311.2K311.2K+$2M$2M
ARGXARGEN SENEW+3.6K3.6K+$1M$1M
IMMATICS NVNEW+105.0K105.0K+$1M$1M
ORICORIC PHARMACEUTICALS INCNEW+72.8K72.8K+$669,732$669,732
VTGNVISTAGEN THERAPEUTICS INCNEW+41.9K41.9K+$215,294$215,294
MLYSMINERALYS THERAPEUTICS INCNEW+15.2K15.2K+$130,720$130,720
ACELYRIN INCADDED+363.9K371.2K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2023

49 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1SPDR S&P BIOTECH ETFETF10.36%$43M484.0K
2CYTKCYTOKINETICS INChistory →COM NEW8.00%$33M400.0K
3RJR1STEREOTAXIS INChistory →COM NEW5.74%$24M13.68M
4ASCENDIS PHARMA A/SSPONSORED ADR · NOTE 2.250% 4/04.72%$20M4.12M
5IDYAIDEAYA BIOSCIENCES INChistory →COM4.40%$18M516.3K
6SNDXSYNDAX PHARMACEUTICALS INChistory →COM3.85%$16M742.6K
7KARUNA THERAPEUTICS INCCOM3.65%$15M48.1K
8RVMDREVOLUTION MEDICINES INChistory →COM3.52%$15M511.9K
9ISHARES NASDAQ BIOTECH INDXETF3.34%$14M102.5K
10XENEXENON PHARMACEUTICALS INChistory →COM3.05%$13M276.7K
11MERUS N VCOM3.00%$13M454.9K
122655787DBLUEPRINT MEDICINES CORPhistory →COM2.45%$10M110.9K
13DAWNGBXDAY ONE BIOPHARMACEUTICALS Ihistory →COM2.40%$10M686.5K
14NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.29%$10M72.6K
15DC4DEXCOM INChistory →COM2.01%$8M67.6K
164XC1KALVISTA PHARMACEUTICALS INChistory →COM1.76%$7M601.0K
17BIOHAVEN LTDCOM1.73%$7M168.8K
18KURAKURA ONCOLOGY INChistory →COM1.70%$7M492.7K
19MORFUSDMORPHIC HOLDING INChistory →COM1.60%$7M231.7K
20TNDMTANDEM DIABETES CARE INChistory →COM NEW1.56%$7M220.7K
21AXGNAXOGEN INChistory →COM1.53%$6M935.9K
22TSVT*2SEVENTY BIO INChistory →COMMON STOCK1.48%$6M1.45M
23IMGNEURIMMUNOGEN INChistory →COM1.38%$6M193.7K
24SG7SAGE THERAPEUTICS INChistory →COM1.27%$5M245.0K
25GALAPAGOS NVSPON ADR1.27%$5M130.2K
26MRTXEURMIRATI THERAPEUTICS INChistory →COM1.26%$5M89.4K
27EWTXEDGEWISE THERAPEUTICS INChistory →COM1.18%$5M449.4K
28ALECALECTOR INChistory →COM1.17%$5M609.9K
29VKTXVIKING THERAPEUTICS INChistory →COM1.11%$5M248.2K
30ATRCATRICURE INChistory →COM1.07%$4M125.5K
31RCUSARCUS BIOSCIENCES INChistory →COM1.07%$4M232.7K
32IPSCCENTURY THERAPEUTICS INChistory →COM1.04%$4M1.31M
33BCRXBIOCRYST PHARMACEUTICALS INChistory →COM1.02%$4M709.5K
34XEJACCURAY INCCOM0.83%$3M1.22M
35CATBUSDASTRIA THERAPEUTICS INCCOM0.83%$3M449.0K
36KROSKEROS THERAPEUTICS INCCOM0.71%$3M74.4K
37ACELYRIN INCCOM0.66%$3M371.2K
38PRCTPROCEPT BIOROBOTICS CORPCOM0.64%$3M63.3K
39MEDIWOUND LTDSHS NEW0.63%$3M257.7K
40BCYCBICYCLE THERAPEUTICS PLCSPONSORED ADS0.53%$2M122.2K
41BWAYBRAINSWAY LTDSPONSORED ADS0.48%$2M308.5K
42PROQR THERAPEUTICS N VSHS EURO0.45%$2M940.6K
43AMLXAMYLYX PHARMACEUTICALS INCCOM0.43%$2M122.5K
44MREOMEREO BIOPHARMA GROUP PLCSPON ADS0.43%$2M778.8K
45IMVTIMMUNOVANT INCCOM0.41%$2M40.7K
46SPRYARS PHARMACEUTICALS INCCOM0.41%$2M311.2K
47CMPSCOMPASS PATHWAYS PLCSPONSORED ADS0.40%$2M193.0K
48SYROS PHARMACEUTICALS INCCOM NEW0.40%$2M214.9K
49SPRUCE BIOSCIENCES INCCOM0.39%$2M548.5K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$440M83May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$431M77Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$405M75Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$362M76Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$353M83May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$393M82Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$423M84Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$419M83Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$439M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$417M76Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$321M75Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$366M73Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$334M72May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$355M79Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$372M87Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$367M90Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$384M94May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$398M87Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$377M80Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$478M84Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$421M89May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$336M74Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$308M80Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$347M87Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$240M80May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$291M81Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$266M89Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$266M87Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$232M79May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$201M83Feb 14, 201913F-HRchanges · EDGAR ↗

Other Included Managers

This filing reports holdings on behalf of 1 additional manager.

  • Fischel Nathan028-12328

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.